<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1550">
  <stage>Registered</stage>
  <submitdate>3/11/1994</submitdate>
  <approvaldate>3/11/1994</approvaldate>
  <actrnumber>ACTRN12607000037404</actrnumber>
  <trial_identification>
    <studytitle>IBCSG VIII - Adjuvant therapy in pre- and peri-menopausal patients with node negative breast cancer</studytitle>
    <scientifictitle>Adjuvant therapy in pre- and peri-menopausal patients with node negative breast cancer</scientifictitle>
    <utrn />
    <trialacronym>IBCSG VIII</trialacronym>
    <secondaryid>National Clinical Trials Registry: NCTR58</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Breast Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Arm B: Luteinising hormone- releasing hormone (LH-RH) analogue - Zoladex (3.6 mg subcutaneous injection every 28 days) x 24 months
Arm C: CMF x 6 months (Cyclophosphamide (100mg/m^2 orally days 1-14), Methotrexate (40mg/m^2 iv  days 1 &amp; 8) and 5-Fluorouracil (600mg/m^2iv  days 1 &amp; 8))
Arm D: CMF x 6 months (Cyclophosphamide (100mg/m^2 orally days 1-14), Methotrexate (40mg/m^2 iv  days 1 &amp; 8) and 5-Fluorouracil (600mg/m^2 iv  days 1 &amp; 8)) followed by LH-RH analogue (Zoladex  3.6 mg subcutatneous injection every 28 days) x 18 months</interventions>
    <comparator>Arm A: No adjuvant therapy (arm discontinued 2/04/1992)</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary endpoint for evaluation of therapeutic effect will be disease-free survival (DFS) where all relapses, second primary tumours and death without recurrence are counted as failures.</outcome>
      <timepoint>Patients are followed up and assessed in clinic after every CMF and LH-RH (lutenising hormone-releasing hormone) analogue administration.  Follow-up is required ever third month during the first two years, every six months for the next three years and yearly thereafter for life.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint>Patients are followed up and assessed in clinic after every CMF and LH-RH (lutenising hormone-releasing hormone) analogue administration.  Follow-up is required ever third month during the first two years, every six months for the next three years and yearly thereafter for life.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patterns of relapse</outcome>
      <timepoint>Patients are followed up and assessed in clinic after every CMF and LH-RH (lutenising hormone-releasing hormone) analogue administration.  Follow-up is required ever third month during the first two years, every six months for the next three years and yearly thereafter for life.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment-related side effects will also be assessed.</outcome>
      <timepoint>Patients are followed up and assessed in clinic after every CMF and LH-RH (lutenising hormone-releasing hormone) analogue administration.  Follow-up is required ever third month during the first two years, every six months for the next three years and yearly thereafter for life.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Systemic disease-free survival.</outcome>
      <timepoint>Will be monitored at regular intervals (6 monthly Data Safety and Monitoring Committee Meetings) for possible early termination of patient entry.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria> Node negative disease Patients must have had:a) Either total mastectomy or breast-conserving procedureb) Axillary clearance with at least 8 lymph nodes for pathological examinationc) The surgical procedure within 6 weeks prior to randomisation At least 8 lymph nodes histo-pathologically examined Tumour confirmed to breast with no detected metastases Adequate marrow function Documented evidence of adequate renal and hepatic function Informed consent Pre- and perimenopausal patients: a) &gt; 52 years, and have had LNMP (last normal menstrual period) within 1 year; orb) &lt; or equal to 52 years, and have had the LNMP within 3 years, or are currently menstruating; orc) &lt; or equal to 55 years and have had hysterectomy without bilateral oophorectomy; ord) Biochemical confirmation of continuing ovarian function</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria> Axillary node involvement Malignant breast tumours other than carcinoma T4 tumours with ulceration or infiltration of the skin, peau d'orange, or metastatic disease Bilateral malignancies, or mass in opposite breast, unless mass is proven by biopsy to be non-malignant Patients who have had less than total mastectomy procedure in which margins of resection contained tumour cells, after which they did not subsequently undergo a total mastectomy  Pregnant at diagnosis or lactating patients (including those who have stopped lactating within past 6 months) Previous or concurrent malignancy, except patients with squamous or basal cell carcinoma of skin, or adequately treated in-situ carcinoma of cervix Prior therapy for breast cancer, including irradiation, surgery or chemo- and/or hormonal therapy Other non-malignant systemic diseases preventing treatment options or prolonged follow-up Psychiatric or addictive disorders preventing informed consent or treatment options Bone scan showing hot spots which cannot be confirmed as benign disease or skeletal pain of unknown cause Older than 45 years who have had a hysterectomy, unless there is chemical proof of ovarian function by all of the following tests: Luteinising Hormone (LH), Follicle Stimulating Hormone (FSH), Oestradiol (E2) (Addendum 1  1/11/1991) Estrogen receptor negative tumours or who are estrogen receptor status unknown (Addendum 7 - 1/08/1998)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by phone and fax</concealment>
    <sequence>Computer generated stratified blocks</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>N/A</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/03/1990</anticipatedstartdate>
    <actualstartdate>29/05/1990</actualstartdate>
    <anticipatedenddate />
    <actualenddate>1/10/1999</actualenddate>
    <samplesize>1200</samplesize>
    <actualsamplesize>1111</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>International Breast Cancer Study Group</primarysponsorname>
    <primarysponsoraddress>Effingerstrasse 40, 3008 Bern</primarysponsoraddress>
    <primarysponsorcountry>Switzerland</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Australia and New Zealand Breast Cancer Trials Group</fundingname>
      <fundingaddress>PO BOX 155
HRMC NSW 2310</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Australia and New Zealand Breast Cancer Trials Group</sponsorname>
      <sponsoraddress>PO BOX 155
HRMC NSW 2310</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>IBCSG VIII is a randomised clinical trial designed to test the therapeutic role of short duration ovarian function suppression (using Zoladex) in pre-/perimenopausal patients with node negative breast cancer.</summary>
    <trialwebsite />
    <publication>N/A</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Dubbo Base Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Newcastle Mater Misericordiae Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Prince of Wales Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Prince Alfred Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Flinders Medical Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Launceston General Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Albury Base Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Alfred Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Austin Health</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Bendigo Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Box Hill Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Geelong Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Melbourne Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>1/03/1990</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St Vincent's Hospital, Melbourne</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Western Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Auckland Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>John F Forbes</name>
      <address>ANZBCTG
PO BOX 155
HRMC NSW 2310</address>
      <phone>+61 2 4985 0159</phone>
      <fax>+ 61 2 4960 1539</fax>
      <email>enquiries@anzbctg.org</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Corinna Beckmore</name>
      <address>ANZBCTG
PO BOX 155
HRMC NSW 2310</address>
      <phone>+61 2 4985 0159</phone>
      <fax>+61 2 4985 0141</fax>
      <email>enquiries@anzbctg.org</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>John F Forbes</name>
      <address>ANZBCTG
PO BOX 155
HRMC NSW 2310</address>
      <phone>+61 2 4985 0113</phone>
      <fax />
      <email>enquiries@anzbctg.org</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>